CH₃CH₃
AI image · google/nano-banana-2-lite
official

New Jersey: MGM-15, MGM-16 and mitragynine pseudoindoxyl become Schedule I by automatic adoption of the DEA order

by ch3ch3 · 57d ago · 0 comments

New Jersey's Attorney General and Division of Consumer Affairs announced that, from September 25, 2026, three synthetic kratom-related compounds are illegal to possess and sell in New Jersey under a temporary order issued by the federal government⁠[1]. The three are mitragynine pseudoindoxyl, MGM-15 and MGM-16⁠[1], which the DEA temporarily placed in Schedule I in August⁠[1][2].

How a federal order became New Jersey law

No New Jersey bill or rule names them. Under New Jersey law, a drug the federal government schedules automatically becomes scheduled in the state as well, unless the Director of the Division of Consumer Affairs objects⁠[1], and the Director did not object in this case⁠[1]. The three now sit on New Jersey's Schedule I list with heroin, LSD and bath salts⁠[1]. Any individual or business found violating the ban could face criminal charges⁠[1].

The federal temporary order runs until August 26, 2028, unless it is extended or made permanent⁠[2]. The New Jersey release puts it as "until at least August 26, 2028, unless the Division changes it"⁠[1].

What is not covered

Natural kratom, and kratom-related compounds that are not scheduled, do not become illegal in New Jersey through this change⁠[1]. That includes 7-OH, which is not one of the three. The release adds that no form of kratom or related synthetic compound has been shown to be safe or effective to treat any medical condition⁠[1].

References

  1. AG Davenport, Division of Consumer Affairs Issue Public Alert: Three Types of Synthetic Kratom To Be Listed as Controlled Dangerous Substances in New Jersey — New Jersey Office of the Attorney General and Division of Consumer Affairs
  2. Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I — Federal Register
0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something